Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6411 posts found.

FDA grants accelerated approval for advanced non-small cell lung cancer treatment

July 4, 2025 Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …
News

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025 Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
News

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025 Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
News

Carthera receives EMA endorsement for orphan medical device status of SonoCloud

July 2, 2025 Medical Communications, Research and Development Brain disorders, Breakthough Device Designation, CE marking, Carthera, Devices, European Medicines Agency (EMA), Food and Drug Administration, Forfait Innovation Status, Neurology, Orphan Medical Device Status, ultrasound imaging

French biotech company Carthera has announced that its SonoCloud system has been granted orphan medical device status by the European …
News
surgery

SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant

July 1, 2025 Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine

SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …
News

PharmNovo submits CTA for non-addictive neuropathic pain therapeutic

July 1, 2025 Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome

Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
News
hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025 Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
News

Inizio Evoke appoints Kelly Cusumano to drive strategic growth and innovation

June 27, 2025 Business Services, Marketing Consultancies, Medical Communications Corporate, Evoke Comms, Inizio Evoke, business strategist, executive vice president, marketing and communications

Inizio Evoke, a global health marketing and communications platform, has appointed Kelly Cusumano as executive vice president, growth and client …
Appointment

PMGroup/Visions4Health unveil Excellence in Healthcare Partnerships Awards

June 26, 2025 Medical Communications CHASE, Corporate, Excellence in Healthcare Partnerships Awards, NHS ConfedExpo, PMGroup, Visions4Health

PMGroup Worldwide and Visions4Health have launched the Excellence in Healthcare Partnerships (EHP) Awards to recognise collaborations that deliver measurable benefits …
News

CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany

June 26, 2025 Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access

CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
News
money_pills_2

Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses

June 26, 2025 Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation

Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …
News

NHS ConfedExpo 2025: a platform for change in UK health and care

June 24, 2025 Medical Communications Accenture, AstraZeneca, Corporate, Excellence in healthcare Partnership (EHP) Awards, Manchester, NHS ConfedExpo, NHS Confederation, NHS England, Novartis UK, Visions4Health

This year’s NHS ConfedExpo took place on 11 to 12 June at Manchester Central, bringing together around 9,000 attendees. Among …
News
handshake_2

AOTI achieves broad market access in Germany for diabetic foot ulcer therapy

June 23, 2025 Market Access, Medical Communications, Sales and Marketing AOTI, Diabetes, European pharma market, German pharma market, Wound Healing, diabetic foot ulcers, market access, positive recommendation

AOTI, focused on solutions for severe and chronic wounds, has announced that its unique topical wound oxygen (TWO2) therapy has …
News
blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

June 23, 2025 Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
News

NICE recommends spevigo for rare and severe psoriasis flares

June 20, 2025 Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …
News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026